Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149
Lake Street analyst Daniel Brims initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $149.
Stocks · News reference
Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Spruce Biosciences Launches MPS3BStudy.com, Online Resource For Families And Caregivers Of Children With Sanfilippo Syndrome Type B
Website Enables Families and Caregivers of Children with MPS IIIB to Learn About and Register Interest in the TA-ERT Expanded Access Program (EAP) and TrAnsform Confirmatory StudyTA-ERT EAP and TrAnsform Confirmatory
Spruce Biosciences Says It Completed Two Pre-BLA Meetings With FDA Supporting Q4 2026 BLA Submission For Tralesinidase Alfa In Sanfilippo Syndrome Type B; FDA Found CMC Comparability Strategies Reasonable